Table 3.
HOXC11 and LSH Expression in Kaplan–Meier Plotter Gastric Cancer Datasets
| Items | No.(%) | Median Survival Time of HOXC11, Month | Median Survival Time of LSH, Month | ||||
|---|---|---|---|---|---|---|---|
| High | Low | P | High | Low | P | ||
| All | 876 | 20.5 | 40.2 | 0.0001 | 10.0 | 36.4 | 0.0001 |
| Gender | |||||||
| Male | 69.8% | 20.3 | 35.8 | 0.0003 | 14.5 | 34.7 | 0.0001 |
| Female | 30.2% | 17.4 | 77.2 | 0.0003 | 28.7 | 45.2 | 0.0999 |
| Tumor invasion(T) | |||||||
| T1 | 2.8% | – | – | – | – | – | – |
| T2 | 48.5% | – | – | 0.0460 | – | 87.0 | 0.0329 |
| T3 | 41.0% | 20.3 | 27.5 | 0.0154 | 20.0 | 27.8 | 0.0199 |
| T4 | 7.6% | 31.6 | 12.0 | 0.0005 | 36.4 | 16.4 | 0.1082 |
| Lymph node metastasis(N) | |||||||
| N0 | 14.9% | 123.8 | 113.2 | 0.0547 | – | 123.6 | 0.3063 |
| N1+2+3 | 85.1% | 32.1 | 45.8 | 0.1236 | 53.0 | 33.3 | 0.0639 |
| N1 | 45.4% | 57.8 | – | 0.0980 | – | 70.2 | 0.0569 |
| N2 | 24.4% | 24.4 | 30.4 | 0.3104 | 30.2 | 21.2 | 0.0812 |
| N3 | 15.3% | 16.2 | 12.3 | 0.0182 | 17.4 | 12.3 | 0.2606 |
| Metastasis(M) | |||||||
| M0 | 88.8% | 46.0 | 113.2 | 0.0240 | 113.2 | 56.9 | 0.0624 |
| M1 | 11.2% | 11.0 | 11.8 | 0.4910 | 11.4 | 11.0 | 0.0521 |
| Stage | |||||||
| I | 10.2% | – | – | 0.1355 | – | 113.2 | 0.1344 |
| II | 21.2% | 123.8 | 123.6 | 0.0539 | – | 123.6 | 0.1597 |
| III | 46.2% | 25.5 | 44.0 | 0.0013 | 25.9 | 34.4 | 0.0479 |
| IV | 22.4% | 17.0 | 15.9 | 0.0029 | 17.4 | 14.3 | 0.0790 |
| Differentiation | |||||||
| Well | 12.1% | 27.4 | – | 0.0046 | 26.6 | – | 0.0054 |
| Middle | 25.4% | 22.3 | 113.2 | 0.0866 | 41.2 | 22.3 | 0.2249 |
| Poor | 62.5% | 32.6 | 24.4 | 0.2540 | 15.4 | 40.0 | 0.0009 |
| Lauren classification | |||||||
| Intestinal | 54.0% | 28.0 | 99.4 | 0.0003 | 28.7 | 85.8 | 0.0185 |
| Diffuse | 40.6% | 15.7 | 44.7 | 0.0034 | 44.7 | 31.1 | 0.0630 |
| Mixed | 5.4% | 25.5 | 78.6 | 0.1397 | – | 32.6 | 0.0952 |
| HER2 | |||||||
| Negative | 60.7% | 26.7 | 46.8 | 0.0007 | 26.7 | 44.6 | 0.0160 |
| Positive | 39.3% | 17.5 | 30.4 | 0.0005 | 14.6 | 29.1 | 0.0001 |
Abbreviations: GAC, gastric adenocarcinoma; GC, gastric carcinoma; GCO, Global Cancer Observatory; HOX, homeobox; HD, homeodomain; RCC, renal cell carcinoma; LSH, lymphoid-specific helicase; PRC, polycomb repressive complex.